Investigation into the Feasibility of Thioditaloside as a Novel Scaffold for Galectin-3-Specific Inhibitors
Author
Summary, in English
Galectin-3 is extensively involved in metabolic and disease processes, such as cancer metastasis, thus giving impetus for the design of specific inhibitors targeting this -galactose-binding protein. Thiodigalactoside (TDG) presents a scaffold for construction of galectin inhibitors, and its inhibition of galectin-1 has already demonstrated beneficial effects as an adjuvant with vaccine immunotherapy, thereby improving the survival outcome of tumour-challenged mice. A novel approachreplacing galactose with its C2 epimer, taloseoffers an alternative framework, as extensions at C2 permit exploitation of a galectin-3-specific binding groove, thereby facilitating the design of selective inhibitors. We report the synthesis of thioditaloside (TDT) and crystal structures of the galectin-3 carbohydrate recognition domain in complexes with TDT and TDG. The different abilities of galactose and talose to anchor to the protein correlate with molecular dynamics studies, likely explaining the relative disaccharide binding affinities. The feasibility of a TDT scaffold to enable access to a particular galectin-3 binding groove and the need for modifications to optimise such a scaffold for use in the design of potent and selective inhibitors are assessed.
Department/s
- Division of Microbiology, Immunology and Glycobiology - MIG
- Centre for Analysis and Synthesis
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
Publishing year
2013
Language
English
Pages
1331-1342
Publication/Series
ChemBioChem
Volume
14
Issue
11
Document type
Journal article
Publisher
John Wiley & Sons Inc.
Topic
- Immunology in the medical area
- Microbiology in the medical area
Keywords
- carbohydrates
- chemical synthesis (thioditaloside)
- inhibitors
- molecular dynamics
- protein structures
Status
Published
ISBN/ISSN/Other
- ISSN: 1439-4227